Recombinant hepatitis b vaccine is the second generation of hepatitis b vaccine developed by genetic engineering technology.
The global Hepatitis B Vaccine (Recombinant) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the Hepatitis B Vaccine (Recombinant) production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Hepatitis B Vaccine (Recombinant) by regions (countries) and by Application.
The global Hepatitis B Vaccine (Recombinant) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Hepatitis B Vaccine (Recombinant) market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Hepatitis B Vaccine (Recombinant) markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Hepatitis B Vaccine (Recombinant) market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Hepatitis B Vaccine (Recombinant) market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Hepatitis B Vaccine (Recombinant) market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Hepatitis B Vaccine (Recombinant) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each application segment for the same period.
This report includes the following manufacturers:
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Market Segment by Type
10mcg/0.5ml
10mcg/ml
Market Segment by Application
Newborn
Adult
Research Methodology
To compile the detailed study of the global Hepatitis B Vaccine (Recombinant) market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Hepatitis B Vaccine (Recombinant) market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Hepatitis B Vaccine (Recombinant) market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
The global Hepatitis B Vaccine (Recombinant) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the Hepatitis B Vaccine (Recombinant) production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Hepatitis B Vaccine (Recombinant) by regions (countries) and by Application.
The global Hepatitis B Vaccine (Recombinant) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Hepatitis B Vaccine (Recombinant) market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Hepatitis B Vaccine (Recombinant) markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Hepatitis B Vaccine (Recombinant) market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Hepatitis B Vaccine (Recombinant) market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Hepatitis B Vaccine (Recombinant) market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Hepatitis B Vaccine (Recombinant) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Hepatitis B Vaccine (Recombinant) market by each application segment for the same period.
This report includes the following manufacturers:
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Market Segment by Type
10mcg/0.5ml
10mcg/ml
Market Segment by Application
Newborn
Adult
Research Methodology
To compile the detailed study of the global Hepatitis B Vaccine (Recombinant) market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Hepatitis B Vaccine (Recombinant) market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Hepatitis B Vaccine (Recombinant) market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Type
1.2.2 10mcg/0.5ml
1.2.3 10mcg/ml
1.3 Market Segment by Application
1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Newborn
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Hepatitis B Vaccine (Recombinant) Market Size (2016-2027)
2.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue (2016-2027)
2.1.2 Global Hepatitis B Vaccine (Recombinant) Sales (2016-2027)
2.2 Global Hepatitis B Vaccine (Recombinant) Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Regions (2016-2021)
2.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Regions (2016-2021)
2.3 Global Hepatitis B Vaccine (Recombinant) Market Size Forecast by Region
2.3.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Region (2022-2027)
2.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Region (2022-2027)
2.4 Global Top Hepatitis B Vaccine (Recombinant) Regions (Countries) Ranking by Market Size
2.5 Hepatitis B Vaccine (Recombinant) Industry Trends
2.5.1 Hepatitis B Vaccine (Recombinant) Market Trends
2.5.2 Hepatitis B Vaccine (Recombinant) Market Drivers
2.5.3 Hepatitis B Vaccine (Recombinant) Market Challenges
2.5.4 Hepatitis B Vaccine (Recombinant) Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Hepatitis B Vaccine (Recombinant) Manufacturers by Sales (2016-2021)
3.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers (2016-2021)
3.1.2 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Hepatitis B Vaccine (Recombinant) Sales in 2020
3.2 Global Top Manufacturers Hepatitis B Vaccine (Recombinant) by Revenue
3.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers (2016-2021)
3.2.2 Top Hepatitis B Vaccine (Recombinant) Manufacturers Covered: Ranking by Revenue
3.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Hepatitis B Vaccine (Recombinant) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis B Vaccine (Recombinant) as of 2020)
3.4 Global Hepatitis B Vaccine (Recombinant) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Hepatitis B Vaccine (Recombinant) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Hepatitis B Vaccine (Recombinant) Market
3.7 Key Manufacturers Hepatitis B Vaccine (Recombinant) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Hepatitis B Vaccine (Recombinant) Market Size by Type
4.1 Global Hepatitis B Vaccine (Recombinant) Historic Market Review by Type (2016-2021)
4.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2016-2021)
4.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2016-2021)
4.1.3 Hepatitis B Vaccine (Recombinant) Price by Type (2016-2021)
4.2 Global Hepatitis B Vaccine (Recombinant) Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Type (2022-2027)
4.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Type (2022-2027)
4.2.3 Hepatitis B Vaccine (Recombinant) Price Forecast by Type (2022-2027)
5 Global Hepatitis B Vaccine (Recombinant) Market Size by Application
5.1 Global Hepatitis B Vaccine (Recombinant) Historic Market Review by Application (2016-2021)
5.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2016-2021)
5.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2016-2021)
5.1.3 Hepatitis B Vaccine (Recombinant) Price by Application (2016-2021)
5.2 Global Hepatitis B Vaccine (Recombinant) Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Application (2022-2027)
5.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Application (2022-2027)
5.2.3 Hepatitis B Vaccine (Recombinant) Price Forecast by Application (2022-2027)
6 North America
6.1 North America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
6.1.1 North America Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
6.1.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
6.2 North America Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
6.2.1 North America Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
6.2.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
6.3 North America Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
6.3.1 North America Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
6.3.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
6.4 North America Hepatitis B Vaccine (Recombinant) Market Size by Country
6.4.1 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
6.4.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
7.1.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
7.1.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
7.2 Europe Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
7.2.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
7.2.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
7.3 Europe Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
7.3.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
7.3.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
7.4 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country
7.4.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
7.4.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
8.1.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
8.1.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
8.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
8.2.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
8.2.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
8.3 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
8.3.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
8.3.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
8.4 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Regions
8.4.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Regions
8.4.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
9.1.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
9.1.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
9.2 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
9.2.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
9.2.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
9.3 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
9.3.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
9.3.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
9.4 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country
9.4.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
9.4.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
10.1.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
10.1.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
10.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
10.2.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
10.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
10.3.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
10.4 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country
10.4.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
10.4.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 GSK Hepatitis B Vaccine (Recombinant) Products and Services
11.1.5 GSK Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.1.6 GSK Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Merck Hepatitis B Vaccine (Recombinant) Products and Services
11.2.5 Merck Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.2.6 Merck Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Corporation Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Products and Services
11.3.5 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.3.6 Sanofi Pasteur Recent Developments
11.4 Dynavax Technologies
11.4.1 Dynavax Technologies Corporation Information
11.4.2 Dynavax Technologies Overview
11.4.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Products and Services
11.4.5 Dynavax Technologies Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.4.6 Dynavax Technologies Recent Developments
11.5 LG Life Sciences
11.5.1 LG Life Sciences Corporation Information
11.5.2 LG Life Sciences Overview
11.5.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Products and Services
11.5.5 LG Life Sciences Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.5.6 LG Life Sciences Recent Developments
11.6 KM Biologics
11.6.1 KM Biologics Corporation Information
11.6.2 KM Biologics Overview
11.6.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 KM Biologics Hepatitis B Vaccine (Recombinant) Products and Services
11.6.5 KM Biologics Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.6.6 KM Biologics Recent Developments
11.7 Shenzhen Kangtai Biological Products
11.7.1 Shenzhen Kangtai Biological Products Corporation Information
11.7.2 Shenzhen Kangtai Biological Products Overview
11.7.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Products and Services
11.7.5 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.7.6 Shenzhen Kangtai Biological Products Recent Developments
11.8 Serum Institute
11.8.1 Serum Institute Corporation Information
11.8.2 Serum Institute Overview
11.8.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Serum Institute Hepatitis B Vaccine (Recombinant) Products and Services
11.8.5 Serum Institute Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.8.6 Serum Institute Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
12.2 Hepatitis B Vaccine (Recombinant) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatitis B Vaccine (Recombinant) Production Mode & Process
12.4 Hepatitis B Vaccine (Recombinant) Sales and Marketing
12.4.1 Hepatitis B Vaccine (Recombinant) Sales Channels
12.4.2 Hepatitis B Vaccine (Recombinant) Distributors
12.5 Hepatitis B Vaccine (Recombinant) Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Type
1.2.2 10mcg/0.5ml
1.2.3 10mcg/ml
1.3 Market Segment by Application
1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Newborn
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Hepatitis B Vaccine (Recombinant) Market Size (2016-2027)
2.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue (2016-2027)
2.1.2 Global Hepatitis B Vaccine (Recombinant) Sales (2016-2027)
2.2 Global Hepatitis B Vaccine (Recombinant) Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Regions (2016-2021)
2.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Regions (2016-2021)
2.3 Global Hepatitis B Vaccine (Recombinant) Market Size Forecast by Region
2.3.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Region (2022-2027)
2.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Region (2022-2027)
2.4 Global Top Hepatitis B Vaccine (Recombinant) Regions (Countries) Ranking by Market Size
2.5 Hepatitis B Vaccine (Recombinant) Industry Trends
2.5.1 Hepatitis B Vaccine (Recombinant) Market Trends
2.5.2 Hepatitis B Vaccine (Recombinant) Market Drivers
2.5.3 Hepatitis B Vaccine (Recombinant) Market Challenges
2.5.4 Hepatitis B Vaccine (Recombinant) Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Hepatitis B Vaccine (Recombinant) Manufacturers by Sales (2016-2021)
3.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers (2016-2021)
3.1.2 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Hepatitis B Vaccine (Recombinant) Sales in 2020
3.2 Global Top Manufacturers Hepatitis B Vaccine (Recombinant) by Revenue
3.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers (2016-2021)
3.2.2 Top Hepatitis B Vaccine (Recombinant) Manufacturers Covered: Ranking by Revenue
3.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Hepatitis B Vaccine (Recombinant) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis B Vaccine (Recombinant) as of 2020)
3.4 Global Hepatitis B Vaccine (Recombinant) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Hepatitis B Vaccine (Recombinant) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Hepatitis B Vaccine (Recombinant) Market
3.7 Key Manufacturers Hepatitis B Vaccine (Recombinant) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Hepatitis B Vaccine (Recombinant) Market Size by Type
4.1 Global Hepatitis B Vaccine (Recombinant) Historic Market Review by Type (2016-2021)
4.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2016-2021)
4.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2016-2021)
4.1.3 Hepatitis B Vaccine (Recombinant) Price by Type (2016-2021)
4.2 Global Hepatitis B Vaccine (Recombinant) Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Type (2022-2027)
4.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Type (2022-2027)
4.2.3 Hepatitis B Vaccine (Recombinant) Price Forecast by Type (2022-2027)
5 Global Hepatitis B Vaccine (Recombinant) Market Size by Application
5.1 Global Hepatitis B Vaccine (Recombinant) Historic Market Review by Application (2016-2021)
5.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2016-2021)
5.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2016-2021)
5.1.3 Hepatitis B Vaccine (Recombinant) Price by Application (2016-2021)
5.2 Global Hepatitis B Vaccine (Recombinant) Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Application (2022-2027)
5.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Application (2022-2027)
5.2.3 Hepatitis B Vaccine (Recombinant) Price Forecast by Application (2022-2027)
6 North America
6.1 North America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
6.1.1 North America Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
6.1.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
6.2 North America Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
6.2.1 North America Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
6.2.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
6.3 North America Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
6.3.1 North America Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
6.3.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
6.4 North America Hepatitis B Vaccine (Recombinant) Market Size by Country
6.4.1 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
6.4.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
7.1.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
7.1.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
7.2 Europe Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
7.2.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
7.2.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
7.3 Europe Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
7.3.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
7.3.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
7.4 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country
7.4.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
7.4.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
8.1.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
8.1.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
8.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
8.2.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
8.2.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
8.3 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
8.3.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
8.3.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
8.4 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Regions
8.4.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Regions
8.4.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
9.1.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
9.1.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
9.2 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
9.2.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
9.2.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
9.3 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
9.3.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
9.3.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
9.4 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country
9.4.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
9.4.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Breakdown by Company
10.1.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Company (2016-2027)
10.1.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Company (2016-2027)
10.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Type (2016-2027)
10.2.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Type (2016-2027)
10.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Application (2016-2027)
10.3.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Application (2016-2027)
10.4 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country
10.4.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2027)
10.4.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 GSK Hepatitis B Vaccine (Recombinant) Products and Services
11.1.5 GSK Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.1.6 GSK Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Merck Hepatitis B Vaccine (Recombinant) Products and Services
11.2.5 Merck Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.2.6 Merck Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Corporation Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Products and Services
11.3.5 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.3.6 Sanofi Pasteur Recent Developments
11.4 Dynavax Technologies
11.4.1 Dynavax Technologies Corporation Information
11.4.2 Dynavax Technologies Overview
11.4.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Products and Services
11.4.5 Dynavax Technologies Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.4.6 Dynavax Technologies Recent Developments
11.5 LG Life Sciences
11.5.1 LG Life Sciences Corporation Information
11.5.2 LG Life Sciences Overview
11.5.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Products and Services
11.5.5 LG Life Sciences Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.5.6 LG Life Sciences Recent Developments
11.6 KM Biologics
11.6.1 KM Biologics Corporation Information
11.6.2 KM Biologics Overview
11.6.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 KM Biologics Hepatitis B Vaccine (Recombinant) Products and Services
11.6.5 KM Biologics Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.6.6 KM Biologics Recent Developments
11.7 Shenzhen Kangtai Biological Products
11.7.1 Shenzhen Kangtai Biological Products Corporation Information
11.7.2 Shenzhen Kangtai Biological Products Overview
11.7.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Products and Services
11.7.5 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.7.6 Shenzhen Kangtai Biological Products Recent Developments
11.8 Serum Institute
11.8.1 Serum Institute Corporation Information
11.8.2 Serum Institute Overview
11.8.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Serum Institute Hepatitis B Vaccine (Recombinant) Products and Services
11.8.5 Serum Institute Hepatitis B Vaccine (Recombinant) SWOT Analysis
11.8.6 Serum Institute Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
12.2 Hepatitis B Vaccine (Recombinant) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatitis B Vaccine (Recombinant) Production Mode & Process
12.4 Hepatitis B Vaccine (Recombinant) Sales and Marketing
12.4.1 Hepatitis B Vaccine (Recombinant) Sales Channels
12.4.2 Hepatitis B Vaccine (Recombinant) Distributors
12.5 Hepatitis B Vaccine (Recombinant) Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
